12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On

10. AbCellera Biologics Inc. (NASDAQ:ABCL)

Number of Hedge Fund Holders: 20 

AbCellera Biologics Inc. (NASDAQ:ABCL) is among the Best Pharmaceutical Stocks.

On June 17, 2026,  AbCellera Biologics Inc. (NASDAQ:ABCL) and Jazz Pharmaceuticals entered a preclinical research collaboration, option, and license agreement. The deal is to discover and develop next-generation T-cell multispecific antibodies targeting gastrointestinal cancers and other solid tumors.

The companies said the partnership includes $56 million in upfront payments to AbCellera Biologics Inc. (NASDAQ:ABCL) and up to $792 million in potential option fees and milestone payments for programs Jazz elects to advance. Jazz holds the exclusive option to develop and market resulting therapeutic antibodies.

AbCellera founder and CEO Carl Hansen, Ph.D., said the deal leverages its T-cell engager platform. Hansen described it as a fully integrated system covering discovery to clinical manufacturing, designed for developing multispecific antibodies for difficult-to-treat cancers.

Jazz Pharmaceuticals chief scientific officer in oncology, Josh Allen, Ph.D., said the collaboration is in line with Jazz’s rare disease strategy, growing its oncology focus into GI cancers.

AbCellera Biologics Inc. (NASDAQ:ABCL) works in the making of therapeutic antibodies. It gives an antibody discovery platform that searches, decodes, and analyzes natural immune systems to identify antibodies that can be produced to prevent and treat disease.